Elevance Health, Inc.
396.90USD
-5.0400 (-1.25%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $4.66▼ | $5.1 | 3 | 14 |
| Next quarter | $2.47▼ | $3 | 0 | 1 |
| Current year | $27.16▲ | $26.91 | 0 | 1 |
| Next year | $29.61▲ | $29.25 | 2 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $6.21 | $7.45 | +1.24 (+20.0%) |
| 2026-03-31 | $10.81 | $12.58 | +1.77 (+16.4%) |
| 2025-12-31 | $3.09 | $3.33 | +0.24 (+7.7%) |
| 2025-09-30 | $4.94 | $6.03 | +1.09 (+22.0%) |
324 ratings from 41 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Market Perform | $364 $395 | Jul 17, 2026 |
| RBC Capital | Maintained | Sector Perform | $439 $424 | Jul 16, 2026 |
| Wells Fargo | Maintained | Overweight | $492 $473 | Jul 16, 2026 |
| Guggenheim | Maintained | Buy | $399 $455 | Jul 16, 2026 |
| Barclays | Maintained | Overweight | $480 $457 | Jul 16, 2026 |
| Baird | Maintained | Neutral | $331 $393 | Jul 16, 2026 |
| TD Cowen | Maintained | Buy | $400 $465 | Jul 14, 2026 |
| Truist Securities | Maintained | Buy | $450 $475 | Jul 14, 2026 |
| Wells Fargo | Maintained | Overweight | $391 $492 | Jul 13, 2026 |
| RBC Capital | Maintained | Sector Perform | $358 $439 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $400 $450 | Jul 7, 2026 |
| Bernstein | Maintained | Outperform | $424 $482 | Jul 2, 2026 |
| Mizuho | Maintained | Outperform | $435 $465 | Jun 8, 2026 |
| JP Morgan | Maintained | Overweight | $411 $476 | Jun 8, 2026 |
| B of A Securities | Maintained | Buy | $435 $460 | Jun 4, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $352 $404 | Jun 4, 2026 |
| Truist Securities | Maintained | Buy | $375 $450 | Jun 1, 2026 |
| Barclays | Maintained | Overweight | $408 $480 | May 26, 2026 |
| UBS | Maintained | Buy | $400 $460 | May 22, 2026 |
| Mizuho | Maintained | Outperform | $385 $435 | May 20, 2026 |
| Deutsche Bank | Upgraded from Hold | Buy | $363 $498 | May 20, 2026 |
| B of A Securities | Upgraded from Neutral | Buy | $405 $435 | Apr 29, 2026 |
| JP Morgan | Maintained | Overweight | $397 $411 | Apr 28, 2026 |
| Barclays | Maintained | Overweight | $393 $408 | Apr 24, 2026 |
| Guggenheim | Maintained | Buy | $396 $399 | Apr 24, 2026 |
59 filings from 23 insiders · 13 buy / 5 sell over 6m
Officers and directors of ELV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wessling Erin MOfficer, EVP & Chief Legal Officer | Tax | 255 | $414.78 | $106k | Sep 3, 2026 |
| Wessling Erin MOfficer, EVP & Chief Legal Officer | Tax | 94 | $405.84 | $38k | Sep 2, 2026 |
| Craig Ryan ROfficer, EVP & Chief HR Officer | Tax | 144 | $405.84 | $58k | Sep 2, 2026 |
| PERU RAMIRO GDirector | Buy | 1.0k | $366.05 | $366k | Jul 17, 2026 |
| BOUDREAUX GAIL A KOZIARAChief Executive Officer | Buy | 2.7k | $366.41 | $1.00M | Jul 17, 2026 |
| PENCZEK RONALD WOfficer | Sell | 369 | $403.16 | $149k | Jun 12, 2026 |
| DIXON ROBERT L JRDirector | Sell | 151 | $401.77 | $61k | Jun 11, 2026 |
| PENCZEK RONALD WOfficer | Sell | 1.5k | $403.13 | $617k | May 19, 2026 |
| PENCZEK RONALD WOfficer | Exercise | 1.5k | $271.27 | $451k | May 19, 2026 |
| HAY LEWIS IIIDirector | Grant | 563 | — | — | May 13, 2026 |
| NERI ANTONIO FDirector | Grant | 563 | — | — | May 13, 2026 |
| JALLAL BAHIJADirector | Grant | 563 | — | — | May 13, 2026 |
| PERU RAMIRO GDirector | Grant | 563 | — | — | May 13, 2026 |
| COLLIS STEVEN HOWARDDirector | Grant | 563 | — | — | May 13, 2026 |
| SCHULMAN AMY W.Director | Grant | 563 | — | — | May 13, 2026 |
| DIXON ROBERT L JRDirector | Grant | 563 | — | — | May 13, 2026 |
| STRABLE-SOETHOUT DEANNA DDirector | Grant | 563 | — | — | May 13, 2026 |
| DEVORE SUSAN DDirector | Grant | 563 | — | — | May 13, 2026 |
| SCHNEIDER RYAN M.Director | Grant | 563 | — | — | May 13, 2026 |
| SCHULMAN AMY W.Director | Sell | 26 | $287.50 | $7k | Mar 12, 2026 |
No analyst notes on ELV yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 12 | 7 | 0 | 0 | Buy2.18 |
| 1 mo ago | 3 | 12 | 7 | 0 | 0 | Buy2.18 |
| 2 mo ago | 2 | 12 | 8 | 0 | 0 | Buy2.27 |